{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:18:59Z","timestamp":1794745139812,"version":"4.9.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biopha.2026.119943","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:28:19Z","timestamp":1790195299000},"page":"119943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Repeated clinical trial failures in Alzheimer\u2019s disease: The pitfalls of pursuing epidemiological associations"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0327-7262","authenticated-orcid":false,"given":"Bruno P.","family":"Imbimbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzio","family":"Pomara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9305-3376","authenticated-orcid":false,"given":"Lorenzo","family":"Pini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-4417","authenticated-orcid":false,"given":"Kristian Steen","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2026.119943_bib1","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1038\/s41467-022-32183-6","article-title":"The causes and consequences of Alzheimer's disease: phenome-wide evidence from Mendelian randomization","volume":"13","author":"Korologou-Linden","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119943_bib2","article-title":"Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors","volume":"7","author":"Peters","year":"2021","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.biopha.2026.119943_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13195-019-0529-5","article-title":"The \u201crights\u201d of precision drug development for Alzheimer\u2019s disease","volume":"11","author":"Cummings","year":"2019","journal-title":"Alzheimers Res. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2026.119943_bib4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/jama.2025.21738","article-title":"Valacyclovir treatment of early symptomatic Alzheimer disease: the VALAD randomized clinical trial","volume":"335","author":"Devanand","year":"2026","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.biopha.2026.119943_bib5","first-page":"2905","article-title":"Time to test antibacterial therapy in Alzheimer's disease","volume":"142","author":"Panza","year":"2019","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.biopha.2026.119943_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70458","article-title":"Evidence for causal links between known modifiable risk factors and dementia: a systematic review of Mendelian randomisation studies","volume":"32","author":"Desai","year":"2025","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119943_bib7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00784-020-03764-w","article-title":"Relationship of Porphyromonas gingivalis and Alzheimer's disease: a systematic review of pre-clinical studies","volume":"25","author":"Costa","year":"2021","journal-title":"Clin. Oral. Investig."},{"issue":"1","key":"10.1016\/j.biopha.2026.119943_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau3333","article-title":"Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors","volume":"5","author":"Dominy","year":"2019","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.biopha.2026.119943_bib9","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.neurobiolaging.2014.10.038","article-title":"Periodontal disease associates with higher brain amyloid load in normal elderly","volume":"36","author":"Kamer","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"10","key":"10.1016\/j.biopha.2026.119943_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204941","article-title":"Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice","volume":"13","author":"Ilievski","year":"2018","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119943_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41514-017-0015-x","article-title":"Periodontitis induced by bacterial infection exacerbates features of Alzheimer's disease in transgenic mice","volume":"3","author":"Ishida","year":"2017","journal-title":"npj Aging Mech. Dis."},{"issue":"10","key":"10.1016\/j.biopha.2026.119943_bib12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/13543784.2022.2117605","article-title":"COR388 (atuzaginstat): an investigational gingipain inhibitor for the treatment of Alzheimer disease","volume":"31","author":"Sabbagh","year":"2022","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2026.119943_bib13","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3389\/fimmu.2020.00456","article-title":"A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer's disease","volume":"11","author":"Hampel","year":"2020","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119943_bib14","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","article-title":"A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment","volume":"30","author":"Thal","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"21","key":"10.1016\/j.biopha.2026.119943_bib15","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1212\/01.wnl.0000260269.93245.d2","article-title":"Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial","volume":"68","author":"ADAPT Research Group","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.biopha.2026.119943_bib16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jalz.2010.12.014","article-title":"Extended results of the Alzheimer\u2019s disease anti-inflammatory prevention trial","volume":"7","author":"Breitner","year":"2011","journal-title":"Alzheimers Dement."},{"issue":"3","key":"10.1016\/j.biopha.2026.119943_bib17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.54.3.588","article-title":"A randomized controlled trial of prednisone in Alzheimer\u2019s disease: Alzheimer\u2019s disease cooperative study","volume":"54","author":"Aisen","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119943_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/agm2.70004","article-title":"Effect of steroids on the progression of Alzheimer's dementia: a retrospective chart review","volume":"8","author":"Conic","year":"2025","journal-title":"Aging Med."},{"issue":"11","key":"10.1016\/j.biopha.2026.119943_bib19","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/sj.npp.1301377","article-title":"Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models","volume":"32","author":"Choi","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.biopha.2026.119943_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","article-title":"Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: a randomized clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119943_bib21","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-026-04273-1","article-title":"The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial","volume":"32","author":"Mummery","year":"2026","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119943_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","article-title":"New insights into the role of TREM2 in Alzheimer's disease","volume":"13","author":"Gratuze","year":"2018","journal-title":"Mol. Neurodegener."},{"issue":"2","key":"10.1016\/j.biopha.2026.119943_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimer's disease","volume":"368","author":"Jonsson","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119943_bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/nbdi.2000.0304","article-title":"Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model","volume":"7","author":"Refolo","year":"2000","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2026.119943_bib25","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","article-title":"A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease","volume":"77","author":"Sano","year":"2011","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.biopha.2026.119943_bib26","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.biopha.2026.119943_bib27","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2010.1510","article-title":"Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial","volume":"304","author":"Quinn","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2026.119943_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2026.106316","article-title":"CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial","volume":"129","author":"Yassine","year":"2026","journal-title":"eBioMedicine"},{"issue":"18","key":"10.1016\/j.biopha.2026.119943_bib29","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1073\/pnas.94.18.9866","article-title":"Iron accumulation in Alzheimer disease is a source of redox-generated free radicals","volume":"94","author":"Smith","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2026.119943_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1001\/jamaneurol.2024.3733","article-title":"Deferiprone in Alzheimer disease: a randomized clinical trial","volume":"82","author":"Ayton","year":"2025","journal-title":"JAMA Neurol."},{"issue":"8081","key":"10.1016\/j.biopha.2026.119943_bib31","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-025-09335-x","article-title":"Lithium deficiency and the onset of Alzheimer's disease","volume":"645","author":"Aron","year":"2025","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2026.119943_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003941","article-title":"Association between lithium use and the incidence of dementia and its subtypes: a retrospective cohort study","volume":"19","author":"Chen","year":"2022","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119943_bib33","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/jamaneurol.2026.0072","article-title":"Low-dose lithium for mild cognitive impairment: a pilot randomized clinical trial","volume":"83","author":"Gildengers","year":"2026","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119943_bib34","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamaneurol.2013.284","article-title":"Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore longitudinal study of aging","volume":"70","author":"Thambisetty","year":"2013","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119943_bib35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119943_bib36","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","article-title":"Safety, efficacy and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial","volume":"77","author":"Craft","year":"2020","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119943_bib37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40266-021-00845-7","article-title":"A phase II, single-center, randomized, double-blind, placebo-controlled study of the safety and therapeutic efficacy of intranasal glulisine in amnestic mild cognitive impairment and probable mild Alzheimer's disease","volume":"38","author":"Rosenbloom","year":"2021","journal-title":"Drugs Aging"},{"issue":"12","key":"10.1016\/j.biopha.2026.119943_bib38","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimers Dement."},{"issue":"5","key":"10.1016\/j.biopha.2026.119943_bib39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/jamaneurol.2025.0353","article-title":"GLP-1RA and SGLT2i medications for type 2 diabetes and Alzheimer disease and related dementias","volume":"82","author":"Tang","year":"2025","journal-title":"JAMA Neurol."},{"issue":"10544","key":"10.1016\/j.biopha.2026.119943_bib40","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(26)00459-9","article-title":"Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials","volume":"407","author":"Cummings","year":"2026","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.biopha.2026.119943_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70422","article-title":"Targeting dementia prevention with semaglutide: The case for APOE4 homozygotes","volume":"21","author":"Daly","year":"2025","journal-title":"Alzheimers Dement."},{"issue":"7","key":"10.1016\/j.biopha.2026.119943_bib42","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJMoa2302368","article-title":"Trial of the MIND diet for prevention of cognitive decline in older persons","volume":"389","author":"Barnes","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119943_bib43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13195-021-00783-x","article-title":"Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease","volume":"13","author":"Phillips","year":"2021","journal-title":"Alzheimers Res. Ther."},{"issue":"18","key":"10.1016\/j.biopha.2026.119943_bib44","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1212\/WNL.0000000000000382","article-title":"Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy","volume":"82","author":"Westwood","year":"2014","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.biopha.2026.119943_bib45","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/nm1202-793","article-title":"Serum insulin-like growth factor I regulates brain amyloid-beta levels","volume":"8","author":"Carro","year":"2002","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119943_bib46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13643-025-02792-5","article-title":"Summarizing attributable factors and evaluating risk of bias of Mendelian randomization studies for Alzheimer's dementia and cognitive status: a systematic review and meta-analysis","volume":"14","author":"Meng","year":"2025","journal-title":"Syst. Rev."},{"issue":"21","key":"10.1016\/j.biopha.2026.119943_bib47","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/01.wnl.0000335163.88054.e7","article-title":"MK-677 Protocol 30 Study Group. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial","volume":"71","author":"Sevigny","year":"2008","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119943_bib48","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2026.119943_bib49","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.npp.1300305","article-title":"Increased anticholinergic challenge-induced memory impairment associated with the APOE-epsilon4 allele in the elderly: a controlled pilot study","volume":"29","author":"Pomara","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.biopha.2026.119943_bib50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archpsyc.62.2.209","article-title":"Apolipoprotein E epsilon4 allele and lorazepam effects on memory in high-functioning older adults","volume":"62","author":"Pomara","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3-4","key":"10.1016\/j.biopha.2026.119943_bib51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/03610738508259179","article-title":"Memory performance in individuals with primary degenerative dementia: its similarity to diazepam-induced impairments","volume":"11","author":"Block","year":"1985","journal-title":"Exp. Aging Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119943_bib52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119943_bib53","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.biopha.2026.119943_bib54","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/alz.12453","article-title":"A critical appraisal of tau-targeting therapies for primary and secondary tauopathies","volume":"18","author":"Imbimbo","year":"2022","journal-title":"Alzheimers Dement."},{"issue":"3","key":"10.1016\/j.biopha.2026.119943_bib55","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-026-04206-y","article-title":"Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks","volume":"32","author":"Petersen","year":"2026","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.biopha.2026.119943_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz2387","article-title":"A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease","volume":"6","author":"Mattsson-Carlgren","year":"2020","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.biopha.2026.119943_bib57","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41398-025-03551-9","article-title":"CDK5-mediated hyperphosphorylation of Tau217 impairs neuronal synaptic structure and exacerbates cognitive impairment in Alzheimer's disease","volume":"15","author":"Fu","year":"2025","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.biopha.2026.119943_bib58","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/cpt.70173","article-title":"Mechanistic population pharmacokinetic-pharmacodynamic model of the tau-targeted antibody posdinemab in healthy participants and participants with Alzheimer's disease","volume":"119","author":"P\u00e9rez-Ruixo","year":"2026","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119943_bib59","doi-asserted-by":"crossref","first-page":"8180","DOI":"10.1038\/s41467-023-43929-1","article-title":"High-throughput target trial emulation for Alzheimer's disease drug repurposing with real-world data","volume":"14","author":"Zang","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2026.119943_bib60","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders: towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119943_bib61","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41591-025-03565-2","article-title":"A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease","volume":"31","author":"Oh","year":"2025","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119943_bib62","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/alz.12433","article-title":"Diversity in Alzheimer's disease drug trials: the importance of eligibility criteria","volume":"18","author":"Franzen","year":"2022","journal-title":"Alzheimers Dement."},{"issue":"3","key":"10.1016\/j.biopha.2026.119943_bib63","article-title":"Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab","volume":"17","author":"Molina-Henry","year":"2025","journal-title":"Alzheimers Dement. (Amst."},{"issue":"8","key":"10.1016\/j.biopha.2026.119943_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70469","article-title":"Comparison of plasma p-tau217\/A\u03b242, p-tau217, and A\u03b242\/A\u03b240 biomarkers by race to detect Alzheimer's disease","volume":"21","author":"Cousins","year":"2025","journal-title":"Alzheimers Dement."},{"issue":"6","key":"10.1016\/j.biopha.2026.119943_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2026.100557","article-title":"Barriers and facilitators to recruitment, engagement, and retention of underrepresented populations in dementia prevention research: a scoping review","volume":"13","author":"Rirash","year":"2026","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.biopha.2026.119943_bib66","doi-asserted-by":"crossref","first-page":"393","DOI":"10.14283\/jpad.2022.48","article-title":"The future of AD clinical trials with the advent of anti-amyloid therapies: an CTAD Task Force report","volume":"9","author":"Delrieu","year":"2022","journal-title":"J. Prev. Alzheimers Dis."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:59:23Z","timestamp":1794743963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":66,"alternative-id":["S0753332226009790"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119943","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repeated clinical trial failures in Alzheimer\u2019s disease: The pitfalls of pursuing epidemiological associations","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119943"}}